TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 380427
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (0.102 to 0.238 mg/kg body weight)
Study: 380427
Drug: Intravenous physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous physostigmine (1.00 to 1.67 mg)
Study: 22483445
Drug: Torus mandibularis
Normalized name: Morus alba extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torus mandibularis bone chips combined with PRP gel
Study: 19347685
Drug: EGb 761(R)
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761(R) (240 mg per day)
Study: 19347685
Drug: Donepezil (initially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (initially 5 mg, after 4 weeks 10 mg per day)
Study: 19347685
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (EGb 761(R) and donepezil at the same doses)
Study: 19347685
Drug: Donepezil mono-therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil mono-therapy
Study: 17497280
Drug: tirofiban+heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: tirofiban+heparin
Study: 7859897
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg twice a day
Study: 6161
Drug: Timolol 30
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol 30 to 60 mg daily
Study: 6161
Drug: Propranolol 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 240 to 480 mg daily
Study: 31392559
Drug: CoQ10 100
Normalized name: Walgreens CoQ10 100mg Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 100 mg/day for 2 months
Study: 23847256
Drug: AZD1480 (10-70
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1480 (10-70 mg QD and 20-45 mg b.i.d.)
Study: 21030612
Drug: Monosodium glutamate
Normalized name: Monosodium Glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosodium glutamate (MSG) 2 g
Study: 19426177
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment before 21 weeks of gestation
Study: 16960174
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (5 mg/d as zinc sulfate)
Study: 9075561
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg rectally of diclofenac (n = 31)
Study: 3816879
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg intravenous infusion
Study: 3816879
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral solution
Study: 3816879
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg tablet administration
Study: 28381155
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy intervention (9-month outpatient intervention)
Study: 21927052
Drug: Epidural ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ketamine (30 mg, 3 mL) plus triamcinolone (80 mg, 2 mL) and bupivacaine (0.25%, 3 mL)
Study: 21927052
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injection (80 mg triamcinolone, 2 mL) and 0.25% bupivacaine (3 mL) plus saline (3 mL)
Study: 21927052
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injection with saline
Study: 16612469
Drug: L-carnitine (CG)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine (CG)
Study: 8898645
Drug: Ribavirin plus
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin plus interferon alfa 2a (1200 mg oral ribavirin daily plus 3 million units of recombinant interferon alfa 2a thrice weekly for 24 weeks)
Study: 8898645
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa 2a alone (3 million units thrice weekly for 24 weeks)
Study: 1797521
Drug: Nicotine 0.5
Normalized name: nicotine 0.583 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 0.5 mg
Study: 1797521
Drug: Nicotine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 1.0 mg
Study: 1797521
Drug: Nicotine 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 2.0 mg
Study: 30747773
Drug: BMS-936559 (10-900
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-936559 (10-900 mg)
Study: 30747773
Drug: BMS-936559 (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-936559 (900 mg)
Study: 30747773
Drug: BMS-936559 (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-936559 (at two highest doses)
Study: 19500154
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 1200 mg once-daily with digoxin
Study: 16337719
Drug: MVA-BN (IMVAMUNE)
Normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-BN (IMVAMUNE) vaccine, highest dose (10^8 TCID50)
Study: 16337719
Drug: MVA-BN (IMVAMUNE)
Normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-BN (IMVAMUNE) vaccine
Study: 15344392
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg once a day
Study: 15344392
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg twice a day
Study: 8369980
Drug: Inhaled cetirizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled cetirizine
Study: 3723261
Drug: 2:1 regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2:1 regimen (60 ml WHO‐ORS followed by 30 ml plain water)
Study: 3723261
Drug: Diluted WHO‐ORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted WHO‐ORS (1.5 L water instead of 1 L)
Study: 27181606
Drug: Indacaterol (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol (110 μg) plus Glycopyrronium (50 μg) once daily
Study: 27181606
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 μg) plus Fluticasone (500 μg) twice daily
Study: 24084500
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intravitreal ranibizumab every 4 weeks (Rq4)
Study: 24084500
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg aflibercept every 4 weeks (2q4)
Study: 24084500
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg aflibercept every 4 weeks (0.5q4)
Study: 24084500
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg aflibercept every 8 weeks (2q8)
Study: 20738227
Drug: Dalcetrapib 900
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib 900 mg with atorvastatin (concurrent dosing study)
Study: 20738227
Drug: Dalcetrapib 600
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib 600 mg with atorvastatin (interval dosing study)
Study: 15689804
Drug: Oral steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids (for 1 week)
Study: 15689804
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral steroids
Study: 1395875
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus preoperative chemotherapy (5-FU 1g/m2/d x 5 and cisplatin 20 mg/m2/d x 5)
Study: 29653037
Drug: Manual Titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Titration (MT) technique
Study: 23135529
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus naltrexone (0.7 mg/kg)
Study: 23135529
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus naltrexone (0.7 mg/kg)
Study: 18474932
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate (3 doses, twice daily for 2 weeks)
Study: 16040376
Drug: Pergolide (0.05-0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide (0.05-0.2 mg per day)
Study: 16040376
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one to four tablets per day)
Study: 12444336
Drug: Body-weight-independent (BWI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body-weight-independent (BWI) dosing of cyclosporine A (CsA) 100-300 mg for 12 weeks
Study: 12444336
Drug: Body-weight-dependent (BWD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body-weight-dependent (BWD) dosing of cyclosporine A (CsA) 1.25-5.0 mg/kg for 12 weeks
Study: 12444336
Drug: Intermittent CsA
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent CsA treatment (after period I)
Study: 12444336
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (after period I)
Study: 6207983
Drug: Propranolol (40-320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40-320 mg/day)
Study: 30710418
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene procedures performed/controlled by nursing home staff (n = 25)
Study: 28636435
Drug: Contrast training
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast training programme (isometric + plyometric), twice a week for 10 weeks
Study: 27213949
Drug: Bupropion (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (300 mg/day) + Naltrexone (50 mg/day)
Study: 27213949
Drug: Bupropion (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (300 mg/day) + Placebo
Study: 24489770
Drug: Antibiotic combination
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic combination therapy (amoxicillin, tetracycline, and metronidazole - ATM)
Study: 24489770
Drug: Antibiotic combination
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic combination therapy (ATM)
Study: 21051252
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (1.6 mU/kg/h) for 4 hours before hemodialysis
Study: 15563637
Drug: Arbitrary‐pressure CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbitrary‐pressure CPAP based on body mass index before treatment polysomnography
Study: 12125474
Drug: Calcimax (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcimax (200 mg per capsule, 2 capsules after light supper for 6 months)
Study: 10427881
Drug: Tramadol 1
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1 mg/kg s.c.
Study: 7579506
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant hormone therapy
Study: 2223432
Drug: Nimodipine (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (calcium antagonist)
Study: 22228638
Drug: Sorafenib 200
Normalized name: sorafenib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 200 mg twice daily plus temsirolimus 25 mg weekly (Arm A)
Study: 22228638
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg every morning, 200 mg every night plus tipifarnib 100 mg twice daily (Arm B)
Study: 17928091
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: rapid tapering and withdrawal 91 days after LT
Study: 17928091
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: slow tapering and withdrawal 25 months after LT
Study: 9579769
Drug: Trandolapril (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (0.25 to 16 mg/day)
Study: 7666079
Drug: Suramin and
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suramin and hydrocortisone (cohort A: loading dose followed by continuous infusion)
Study: 7666079
Drug: Suramin and
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suramin and hydrocortisone (cohort C: empiric dosing regimen)
Study: 7666079
Drug: Suramin and
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suramin and hydrocortisone (sequential regimens)
Study: 2572047
Drug: Salicylazosulfapyridine (SASP)
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salicylazosulfapyridine (SASP) treatment
Study: 31186389
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical care with no change in regular daily activities.
Study: 29066877
Drug: Subcutaneous teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous teriparatide (20 μg/day)
Study: 21676992
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of lurasidone
Study: 21676992
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of lurasidone
Study: 21676992
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of olanzapine
Study: 20112596
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day elemental zinc
Study: 9129883
Drug: Vasodilating beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasodilating beta-blockers (e.g., carvedilol)
Study: 9129883
Drug: Standard beta-blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard beta-blockers (e.g., metoprolol)
Study: 8499737
Drug: HDivIg at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDivIg at 500 mg/kg given over 2 h
Study: 3677213
Drug: ASA (1300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA (1300 mg) alone
Study: 3677213
Drug: ASA (1300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA (1300 mg) plus Ranitidine (150 mg)
Study: 31879812
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg intravenous tranexamic acid (IV-TXA) before incision (Group B)
Study: 31879812
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg intravenous tranexamic acid (IV-TXA) before incision (Group A)
Study: 31879812
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg intravenous tranexamic acid (IV-TXA)
Study: 29936239
Drug: G-ICBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-ICBT
Study: 18557720
Drug: CP-690 550
Normalized name: CP
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CP-690 550 15 mg BID
Study: 18557720
Drug: CP-690 550
Normalized name: CP
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CP-690 550 30 mg BID
Study: 15303108
Drug: Lifestyle education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle education group (LE‐G)
Study: 15303108
Drug: Substitutional diet
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substitutional diet with guided physical activity (SD/PA‐G)
Study: 15303108
Drug: Substitutional diet
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substitutional diet without guided physical activity (SD‐G)
Study: 9266888
Drug: MDI albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI albuterol (360 microg)
Study: 9266888
Drug: NEB albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEB albuterol (1.5 mg)
Study: 9266888
Drug: MDI saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI saline solution placebo
Study: 9266888
Drug: NEB saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEB saline solution placebo
Study: 3521619
Drug: Dried garlic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried garlic (3 X 198 mg) in Study I
Study: 3521619
Drug: Dried garlic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried garlic (3 X 450 mg) in Study II
Study: 30683623
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of autogenous and xenogenous bone
Study: 17646564
Drug: Echinacea purpurea
Normalized name: Echinacea purpurea
DrugBank: Echinacea purpurea (DB14239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea purpurea (350 mg single dose)
Study: 7694975
Drug: Cefmetazole 2
Normalized name: cefmetazole 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefmetazole 2 g by intravenous push immediately prior to incision
Study: 7694975
Drug: Cefmetazole 2
Normalized name: cefmetazole 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefmetazole 2 g by intravenous push 15 to 60 minutes prior to incision
Study: 1209435
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of vitamins B6, B1 and B12
Study: 28649870
Drug: Manual dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual dosing of 10 ml radiolabeled Wet® Original® lubricant
Study: 28649870
Drug: Applicator dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applicator dosing of 10 ml radiolabeled hydroxyethyl cellulose universal placebo gel
Study: 28649870
Drug: Applicator dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applicator dosing of 3.5 ml radiolabeled hydroxyethyl cellulose universal placebo gel
Study: 24782286
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg pethidine
Study: 24782286
Drug: 0.1 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 μg/kg sufentanil
Study: 23148048
Drug: 300 g
Normalized name: Zantac 300 GELdose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 g of vegetables and 25 mL PUFA-rich plant oil per day
Study: 12575566
Drug: Baisuifang Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baisuifang Oral Liquid (BSF)
Study: 7946935
Drug: Nimodipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (30 mg three times daily)
Study: 7946935
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 mg once daily)
Study: 7946935
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Nimodipine and Diazepam)
Study: 3062266
Drug: biosynthetic human
Normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: biosynthetic human NPH insulin (controls)
Study: 25581701
Drug: Positive coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive coping strategies (e.g., problem solving, cognitive reframing)
Study: 25581701
Drug: Negative coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative coping strategies (e.g., fighting, breaking things)
Study: 20946583
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bath PUVA and targeted UVB 308 nm excimer radiation
Study: 9315401
Drug: Expectant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectant therapy with metoclopramide
Study: 9315401
Drug: Antiemetic use
Normalized name: ANTIEMETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiemetic use in expectant therapy groups
Study: 2872720
Drug: High-dose fluoxymesterone
Normalized name: Fluoxymesterone
DrugBank: Fluoxymesterone (DB01185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose fluoxymesterone (1 mg/kg/d)
Study: 2872720
Drug: High-dose norethandrolone
Normalized name: norethandrolone
DrugBank: Norethandrolone (DB12787)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose norethandrolone (1 mg/kg/d)
Study: 2872720
Drug: Low-dose fluoxymesterone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fluoxymesterone (0.2 mg/kg/d)
Study: 2872720
Drug: Low-dose norethandrolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose norethandrolone (0.2 mg/kg/d)
Study: 2872720
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of 4 different androgens
Study: 2872720
Drug: Fluoxymesterone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxymesterone (1 mg/kg/d) for 18 months
Study: 29193980
Drug: Estradiol vaginal
Normalized name: Estradiol Vaginal
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol vaginal cream 0.003% (15 μg estradiol; 0.5 g cream), applied vaginally once daily for 2 weeks followed by two applications/week for 10 weeks.
Study: 29193980
Drug: Estradiol vaginal
Normalized name: Estradiol Vaginal
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol vaginal cream 0.003%
Study: 29193980
Drug: Placebo (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5 g cream), applied vaginally once daily for 2 weeks followed by two applications/week for 10 weeks.
Study: 25028375
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) treatment for 3 years
Study: 15882537
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg/HCTZ 12.5 mg daily
Study: 15882537
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 60 mg daily
Study: 12795769
Drug: Alefacept (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept (0.025 mg/kg, 0.075 mg/kg, or 0.150 mg/kg)
Study: 27899759
Drug: Intensive antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive antihypertensive treatment aiming for systolic BP 120-140 mmHg
Study: 27899759
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment aiming for systolic BP 140-180 mmHg
Study: 24635483
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) for solar keratosis (SK) grade I-II.
Study: 23809328
Drug: 0.8g of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8g of c9,t11CLA daily for two months